Available option
10mg
Lyophilised powder
- Strength
- 10mg
- Format
- Lyophilised powder
Bear Biotech catalogue
Tirzepatide
Dual GIP and GLP-1 receptor agonist research material
- GIP receptor signalling
- GLP-1 receptor signalling
- Metabolic physiology
Available presentations
Choose a strength and format
Each available presentation is listed separately. Current prices are confirmed from the Bear Biotech catalogue.
Research overview
What is Tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist backed by extensive controlled human research using defined pharmaceutical formulations. Its scientific importance comes from combining two incretin pathways in one molecule and comparing that biology with single-receptor GLP-1 approaches. Generic research material is not equivalent to an approved medicine.
Extensive randomised human phase 3 evidence for defined pharmaceutical formulations; research vial is not equivalent to an approved product.
Research focus
Key research areas
Tirzepatide research: dual GIP and GLP-1 receptor signalling
Tirzepatide is a peptide designed to activate GIP and GLP-1 receptors. Human studies concern defined pharmaceutical formulations that are not interchangeable with generic material. Published findings concern defined experimental materials and do not establish the identity, quality, safety, efficacy or equivalence of Bear Biotech catalogue material.
- GIP receptor signalling
- GLP-1 receptor signalling
- Metabolic physiology
Representative primary research
Representative research
Research includes dual-incretin receptor signalling, insulin secretion and sensitivity, beta-cell function, glucagon-related markers, appetite and metabolic endpoints.
- SURPASS-1 ↗ Randomised phase 3 human trial; the defined study product does not establish catalogue material equivalence.
- Tirzepatide versus Semaglutide Once Weekly ↗ Randomised phase 3 human trial; the defined study product does not establish catalogue material equivalence.
- Tirzepatide markers of islet function and insulin sensitivity ↗ Human phase-3 post hoc biomarker analysis; it does not establish catalogue material equivalence.
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity ↗ Randomised phase 3 human trial; the defined study product does not establish catalogue material equivalence.
These sources provide research context only. They do not verify the identity, quality or equivalence of a Bear Biotech catalogue batch; the matched lot-specific batch record remains controlling.
Specifications
Product information
- Material identity
- Tirzepatide
- Research category
- Dual GIP and GLP-1 receptor agonist research material
- Evidence position
- Extensive randomised human phase 3 evidence for defined pharmaceutical formulations; research vial is not equivalent to an approved product.
- Recorded formats
- Lyophilised powder
- Batch-record basis
- The matched lot-specific record controls identity and analytical claims.
- Intended use
- Controlled laboratory research only.
Research questions
Evidence and identity questions
What makes Tirzepatide a dual GIP and GLP-1 receptor agonist?
Tirzepatide is studied as a dual GIP- and GLP-1-receptor agonist. Researchers examine how the two incretin pathways contribute to metabolic physiology.
How are the two incretin pathways separated in Tirzepatide research?
GIP- and GLP-1-receptor effects are assessed within defined trial formulations and protocols. Results depend on the exact molecule and preparation.
Why is a generic Tirzepatide vial not equivalent to an approved product?
Tirzepatide has extensive randomised phase 3 human evidence for defined pharmaceutical formulations. A generic research vial is not equivalent to an approved product.
Batch documentation
Lot-specific records stay connected to the order
Eligible lot-specific documentation may be viewed or requested from the registered Bear Biotech account when available for the applicable order.
Open Bear Biotech accountResearch use only
Controlled laboratory research material
Not for human or veterinary consumption. Administration, dosing and therapeutic guidance are not provided.